Rivaroxaban for Deep Vein Thrombosis ((RAMBLE) Trial)

"Apixaban is a medication used to treat deep vein thrombosis, venous thromboembolism, and other conditions like cerebrovascular accident and chronic coronary artery disease."

"Currently, there are 92 ongoing clinical trials worldwide for Apixaban. These trials are taking place in 576 different cities across 48 countries. The first trial for Apixaban was conducted in 2015 by Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma. This trial completed its Phase 3 drug approval stage and involved 2180 patients. Since 2015, there have been 297 total studies conducted."

"Yes, the clinical trial is still active and looking for 50 participants across 2 locations, as stated on clinicaltrials.gov. The trial was first posted on September 1st, 2016 and was last updated on December 4th, 2019."

"To be accepted into this trial, patients must be aged 18 to 50, have venous thromboembolism, and meet the following criteria: non-pregnant women who have active menstruation (this does not apply to women who have recently been pregnant) and must have a working telephone."

"From the eligibility requirements, we can see that only people aged 18 to 50 are able to participate in this trial. There are 8 other clinical trials available for patients under 18 and 159 for seniors."